Kotak Institutional Equities noted that Emcure is one of the few Indian pharmaceutical majors with no direct exposure to the US generics market, which contributes to its earnings stability.
Kotak Institutional Equities noted that Emcure is one of the few Indian pharmaceutical majors with no direct exposure to the US generics market, which contributes to its earnings stability.